Skip to main content

Inhaled medicinal cannabis and the immunocompromised patient


Medicinal cannabis is an invaluable adjunct therapy for pain relief, nausea, anorexia, and mood modification in cancer patients and is available as cookies or cakes, as sublingual drops, as a vaporized mist, or for smoking. However, as with every herb, various microorganisms are carried on its leaves and flowers which when inhaled could expose the user, in particular immunocompromised patients, to the risk of opportunistic lung infections, primarily from inhaled molds. The objective of this study was to identify the safest way of using medicinal cannabis in immunosuppressed patients by finding the optimal method of sterilization with minimal loss of activity of cannabis. We describe the results of culturing the cannabis herb, three methods of sterilization, and the measured loss of a main cannabinoid compound activity. Systematic sterilization of medicinal cannabis can eliminate the risk of fatal opportunistic infections associated with cannabis among patients at risk.

This is a preview of subscription content, access via your institution.

Fig. 1



Medicinal cannabis




  1. 1.

    Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL (2007) Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 82:572–578

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Cescon DW, Page AV, Richardson S, Moore MJ, Boerner S, Gold WL (2008) Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol 26:2214–2215

    PubMed  Article  Google Scholar 

  3. 3.

    Chusid MJ, Gelfand JA, Nutter C, Fauci AS (1975) Letter: pulmonary aspergillosis, inhalation of contaminated marijuana smoke, chronic granulomatous disease. Ann Intern Med 82:682–683

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA (1991) Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 324:654–662

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Gargani Y, Bishop P, Denning DW (2011) Too many mouldy joints—marijuana and chronic pulmonary aspergillosis. Mediterr J Hematol Infect Dis 3:e2011005

    PubMed Central  PubMed  Article  Google Scholar 

  6. 6.

    Hamadeh R, Ardehali A, Locksley RM, York MK (1988) Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. Chest 94:432–433

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Kagen SL (1981) Aspergillus: an inhalable contaminant of marihuana. N Engl J Med 304:483–484

    CAS  PubMed  Google Scholar 

  8. 8.

    Levitz SM, Diamond RD (1991) Aspergillosis and marijuana. Ann Intern Med 115:578–579

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Marks WH, Florence L, Lieberman J, Chapman P, Howard D, Roberts P, Perkinson D (1996) Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Transplantation 61:1771–1774

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Mechoulam R, McCallum NK, Burstein S (1976) Recent advances in the chemistry and biochemistry of cannabis. Chem Rev 76:75–112

    CAS  Article  Google Scholar 

  11. 11.

    Nations U (2009) Recommended methods for the identification and analysis of cannabis and cannabis products. Manual for use by national drug analysis laboratories In: Editor (ed)^(eds) Book Recommended methods for the identification and analysis of cannabis and cannabis products. Manual for use by national drug analysis laboratories Laboratory and Scientific Section, United Nations Office on Drugs and Crime, City.

  12. 12.

    Scheretz RJ, Belani A, Kramer BS et al (1987) Impact of air filtration on nosocomial aspergillus infection: unique risk of bone marrow transplant recipients. Am J Med 83:709–718

    Article  Google Scholar 

  13. 13.

    Schwartz IS (1985) Marijuana and fungal infection. Am J Clin Pathol 84:256

    CAS  PubMed  Google Scholar 

  14. 14.

    Shay AH, Choi R, Whittaker K (2003) Impairment of antibacterial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaine. J Infect Dis 187(4):700–4

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Sutton S, Lum BL, Torti FM (1986) Possible risk of invasive pulmonary aspergillosis with marijuana use during chemotherapy for small cell lung cancer. Drug Intell Clin Pharm 20:289–291

    CAS  PubMed  Google Scholar 

  16. 16.

    Szyper-Kravitz M, Lang R, Manor Y, Lahav M (2001) Early invasive pulmonary aspergillosis in a leukemia patient linked to aspergillus contaminated marijuana smoking. Leuk Lymphoma 42:1433–1437

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Verweij PE, Kerremans JJ, Voss A, Meis JF (2000) Fungal contamination of tobacco and marijuana. JAMA 284:2875

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Weinrieb RM, Lucey MR (2007) Treatment of addictive behaviors in liver transplant patients. Liver Transpl 13:S79–82

    PubMed  Article  Google Scholar 

Download references


The use of medicinal cannabis was approved by the chief national psychiatrist of the Israeli Health Ministry.

Author contributions

Study design and manuscript writing were under the responsibility of Rosa Ruchlemer, David Raveh, Michal Amit-Kohn, and Lumír Hanuš. David Raveh also cultured the cannabis. Lumir Hanus was also responsible for the sterilization studies.

Conflict of interest




Data sharing statement

No additional data available.

Author information



Corresponding author

Correspondence to Rosa Ruchlemer.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ruchlemer, R., Amit-Kohn, M., Raveh, D. et al. Inhaled medicinal cannabis and the immunocompromised patient. Support Care Cancer 23, 819–822 (2015).

Download citation


  • Cannabis
  • Immunocompromised host
  • Aspergillosis